VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) announced today that healthcare information technology executive Robert Watson has joined the Company’s Board of Directors.
Mr. Watson has over 35 years of experience in the healthcare IT industry as a CEO, board member and advisor to multiple companies. Having participated in over 75 acquisitions, he has raised nearly $750,000,000 in capital, completed three public offerings and successfully sold four companies.
Currently, Mr. Watson is President of the Preparedness Technology Division at Intermedix. Prior, he was the President and Chief Growth Officer of NantHealth, and CEO of Streamline Health, both NASDAQ listed companies. He has held executive positions at numerous other healthcare IT companies.
Mr. Watson holds an MBA from the Wharton School of Business at the University of Pennsylvania and a BA from Syracuse University.
“I am excited to join CEL-SCI’s board at this time, as the Company approaches evaluating the endpoint of its Phase 3 results, which may lead to a new and much needed immunotherapy to treat head and neck cancer. The impact CEL-SCI and its investigational immunotherapy Multikine* can have in the cancer treatment market and in improving the quality of life of patients living with the disease may be enormous. I am pleased to contribute my expertise in supporting CEL-SCI,” stated Robert Watson.
“We are so pleased that Robert has joined our board. He brings a depth of knowledge and experience that we believe will add significant value to our board and our Company. His experience encompasses executive leadership at large public companies and the start-up, growth and sale of healthcare companies, as well as investment banking. We welcome him to our board,” CEL-SCI CEO Geert Kersten added.
About CEL-SCI Corporation
CEL-SCI is a Phase 3 cancer immunotherapy company. When it comes to cancer immunotherapy, CEL-SCI believes it is most logical to boost the patient’s immune system while it is still intact in order to have the greatest possible impact on survival. Therefore, CEL-SCI treats patients who are newly diagnosed with head and neck cancer with its lead investigational immunotherapy Multikine, BEFORE they have received surgery, radiation and/or chemotherapy. This approach is unique. Most other cancer immunotherapies are used only after conventional therapies have been tried and/or failed. Head and neck cancer represents about 6% of all cancers. Multikine has received Orphan Drug designation from the FDA for the treatment of head and neck cancer patients with advanced squamous cell carcinoma.
The Company’s LEAPS technology is being developed as a therapeutic vaccine for rheumatoid arthritis and is supported by grants from the National Institutes of Health. CEL-SCI has patents on Multikine from the US, Europe, China, and Japan.
The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI’s filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K and 10-K/A for the year ended September 30, 2016. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine. Further research is required, and early-phase clinical trial results must be confirmed in the Phase 3 clinical trial of this investigational therapy that is in progress.